Moleculin Biotech is trading at $8.95, up 5.79%, after positive interim Annamycin Phase 2/3 trial results showed complete remission rates of 43% and 36% in treatment arms versus 12% for placebo. - The monitoring committee recommended continuing the study unchanged. - Broader conditions were sharply negative, including a reported 5.19% decline in biotech ETF XBI; sector weakness does not explain the rise.